Also known as: Urticaria / Urtication / Urticated rash / Urticarial / Urticarial rash / Rash urticarial / Unspecified urticaria / Urticaria, unspecified / Hives / Urticaria NOS

DrugDrug NameDrug Description
DB00748CarbinoxamineCarbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
DB00283ClemastineAn ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
DB09555Dexchlorpheniramine maleateDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
DB01075DiphenhydramineDiphenhydramine, also known commercially as Benadryl, is a first generation antihistamine that is used primarily for the treatment of seasonal allergies. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system. While its use in in allergies has largely fallen out of favour due to this sedative effect, diphenhydramine has been repurposed for use within many OTC (over the counter) cough-and-cold medications that have been marketed for "night time" use. Diphenhydramine is also used in combination with [DB14132] as the anti-nausea drug [DB00985] where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system [A1540]. Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid [A1539]. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
DB09054IdelalisibIdelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
DB00455LoratadineLoratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. [PubChem]
DrugDrug NameTargetType
DB00748CarbinoxamineHistamine H1 receptortarget
DB00748CarbinoxamineCytochrome P450 2B6enzyme
DB00748CarbinoxamineCytochrome P450 2C19enzyme
DB00748CarbinoxamineCytochrome P450 2C8enzyme
DB00748CarbinoxamineCytochrome P450 2C9enzyme
DB00748CarbinoxamineCytochrome P450 2D6enzyme
DB00748CarbinoxamineCytochrome P450 2E1enzyme
DB00748CarbinoxamineCytochrome P450 3A4enzyme
DB00283ClemastineHistamine H1 receptortarget
DB00283ClemastineCytochrome P450 2D6enzyme
DB00283ClemastineCytochrome P450 3A4enzyme
DB09555Dexchlorpheniramine maleateCytochrome P450 2D6enzyme
DB09555Dexchlorpheniramine maleateHistamine H1 receptortarget
DB09555Dexchlorpheniramine maleateSolute carrier family 22 member 1carrier
DB09555Dexchlorpheniramine maleateSolute carrier family 22 member 2carrier
DB09555Dexchlorpheniramine maleateCytochrome P450 3A4enzyme
DB01075DiphenhydramineHistamine H1 receptortarget
DB01075DiphenhydramineCytochrome P450 2D6enzyme
DB01075DiphenhydramineCytochrome P450 1A2enzyme
DB01075DiphenhydramineCytochrome P450 2C9enzyme
DB01075DiphenhydramineCytochrome P450 2C19enzyme
DB01075DiphenhydramineCytochrome P450 2C18enzyme
DB01075DiphenhydramineCytochrome P450 2B6enzyme
DB01075DiphenhydramineSolute carrier family 22 member 2transporter
DB01075DiphenhydramineSolute carrier family 22 member 1transporter
DB01075DiphenhydramineSolute carrier family 22 member 5transporter
DB01075DiphenhydramineProstaglandin G/H synthase 1enzyme
DB01075DiphenhydramineMuscarinic acetylcholine receptor M2target
DB09054IdelalisibPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)target
DB09054IdelalisibATP-binding cassette sub-family G member 2transporter
DB09054IdelalisibMultidrug resistance protein 1transporter
DB09054IdelalisibAldehyde oxidaseenzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A4enzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A1enzyme
DB09054IdelalisibCytochrome P450 2C8enzyme
DB09054IdelalisibCytochrome P450 2C19enzyme
DB09054IdelalisibCytochrome P450 2B6enzyme
DB09054IdelalisibCytochrome P450 3A4enzyme
DB09054IdelalisibSolute carrier organic anion transporter family member 1B1transporter
DB09054IdelalisibSolute carrier organic anion transporter family member 1B3transporter
DB09054IdelalisibCytochrome P450 3A5enzyme
DB09054IdelalisibCytochrome P450 3A43enzyme
DB09054IdelalisibCytochrome P450 3A7enzyme
DB00455LoratadineHistamine H1 receptortarget
DB00455LoratadineCytochrome P450 3A4enzyme
DB00455LoratadineCytochrome P450 2C19enzyme
DB00455LoratadineCytochrome P450 2D6enzyme
DB00455LoratadineCytochrome P450 2C8enzyme
DB00455LoratadineMultidrug resistance protein 1transporter
DB00455LoratadineCytochrome P450 2C9enzyme
DB00455LoratadinePotassium voltage-gated channel subfamily H member 2target
DrugDrug NamePhaseStatusCount
DB01281Abatacept1 / 2Completed1
DB00026Anakinra1 / 2Terminated1
DB00073Rituximab1 / 2Terminated1
DB06282Levocetirizine3Not Yet Recruiting1
DB06282Levocetirizine4Unknown Status1
DB00169CholecalciferolNot AvailableCompleted1
DB00967DesloratadineNot AvailableCompleted2
DB01234DexamethasoneNot AvailableRecruiting1
DB00751EpinastineNot AvailableCompleted1
DB06282LevocetirizineNot AvailableTerminated1
DB00455LoratadineNot AvailableCompleted1
DB00043OmalizumabNot AvailableUnknown Status1
DB00860PrednisoloneNot AvailableRecruiting1